| scholarly article | Q13442814 |
| P50 | author | Vincenzo Di Stefano | Q88801124 |
| P2093 | author name string | Alessandro Graziosi | |
| Angelika Anna Mohn | |||
| Eleonora Rotondo | |||
| P2860 | cites work | Hepatotoxicity of Herbal Supplements Mediated by Modulation of Cytochrome P450. | Q47166492 |
| Plasma exchange in severe acute relapses of multiple sclerosis - Results from a Portuguese cohort. | Q47309692 | ||
| Incomplete septal cirrhosis after high-dose methylprednisolone therapy and regression of liver injury. | Q50182833 | ||
| Methylprednisolone liver toxicity: A new case and a French regional pharmacovigilance survey. | Q53955037 | ||
| Methylprednisolone-induced acute liver injury in a patient treated for multiple sclerosis relapse. | Q54261884 | ||
| Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. | Q55283252 | ||
| The Development of a Database for Herbal and Dietary Supplement Induced Liver Toxicity | Q57066650 | ||
| Pediatric multiple sclerosis | Q59615980 | ||
| Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS | Q69351477 | ||
| Recurrent acute hepatitis in patient receiving pulsed methylprednisolone for multiple sclerosis | Q79692074 | ||
| Recurrent high-dose intravenous methylprednisolone succinate pulse therapy-induced hepatopathy in a patient with multiple sclerosis | Q83759589 | ||
| Are Leber's mitochondial DNA mutations associated with aquaporin-4 autoimmunity? | Q85649548 | ||
| Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance | Q87024749 | ||
| Repository corticotropin injection in multiple sclerosis: an update | Q88992618 | ||
| Toxic liver injury after high-dose methylprednisolone in people with multiple sclerosis | Q90386102 | ||
| Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria | Q24605493 | ||
| High-dose methylprednisolone-induced hepatitis in a patient with multiple sclerosis: a case report and brief review of literature | Q27006889 | ||
| Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines | Q28216281 | ||
| Multiple sclerosis | Q28299151 | ||
| Relapses in multiple sclerosis: Relationship to disability | Q31072834 | ||
| Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial | Q33589934 | ||
| A mechanistic insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity. | Q34239110 | ||
| Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis | Q34300614 | ||
| Possible hepatotoxicity of chronic marijuana usage | Q34353175 | ||
| Therapeutic strategies in childhood multiple sclerosis | Q34409508 | ||
| Liver injury induced by high-dose methylprednisolone therapy: a case report and brief review of the literature | Q35582456 | ||
| Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy | Q35843262 | ||
| Induced liver injury after high-dose methylprednisolone in a patient with multiple sclerosis | Q35885041 | ||
| Mechanisms of drug-induced liver injury. | Q36439183 | ||
| Disease-modifying therapy of pediatric multiple sclerosis | Q36568645 | ||
| Review article: drug hepatotoxicity | Q36798653 | ||
| Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report | Q37347316 | ||
| Glucocorticoid treatment of multiple sclerosis | Q38186218 | ||
| Recreational drugs: a new health hazard for patients with concomitant chronic liver diseases | Q38201079 | ||
| Drug-induced liver injury: Interactions between drug properties and host factors | Q38442310 | ||
| Outcome of MS relapses in the era of disease-modifying therapy | Q38636590 | ||
| New Perspectives in Pediatric Neurology-Multiple Sclerosis | Q38669849 | ||
| Methylprednisolone-induced liver injury: Case report and literature review | Q38671657 | ||
| Acute Multiple Sclerosis Relapse | Q38854057 | ||
| Pediatric multiple sclerosis: Conventional first-line treatment and general management | Q38940087 | ||
| Hepatotoxicity associated to synthetic cannabinoids use. | Q39221846 | ||
| Corticosteroids in the management of acute multiple sclerosis exacerbations. | Q39229363 | ||
| Incidence of drug-induced hepatic injuries: a French population-based study | Q39609276 | ||
| Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses | Q39868371 | ||
| Hepatotoxicity after high-dose intravenous methylprednisolone in multiple sclerosis patients. | Q41197708 | ||
| Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness | Q41574108 | ||
| Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses. | Q41669067 | ||
| Acute liver toxicity due to methylprednisolone: consider this diagnosis in the context of autoimmunity | Q44411682 | ||
| Recurrent acute liver toxicity from intravenous methylprednisolone | Q46153825 | ||
| Spatiotemporal patterns of dexamethasone-induced Ras protein 1 expression in the central nervous system of rats with experimental autoimmune encephalomyelitis | Q46900163 | ||
| P433 | issue | 1 | |
| P577 | publication date | 2018-12-07 | |
| P1433 | published in | BMJ case reports | Q27723081 |
| P1476 | title | Methylprednisolone-induced hepatotoxicity in a 16-year-old girl with multiple sclerosis | |
| P478 | volume | 11 |
| Q91973934 | Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review | cites work | P2860 |
Search more.